← Eichor
Condition: Ovarian Clear Cell Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Ovarian Clear Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Phase 2 · 16 location(s) · MacroGenics · NCT06730347Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Beva
Phase 3 · 32 location(s) · Genelux Corporation · NCT05281471A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Phase 1/Phase 2 · 4 location(s) · Cancer Research UK · NCT06380816Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Phase 1 · 2 location(s) · Dana-Farber Cancer Institute · NCT06321484Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Phase 2 · 3 location(s) · Centre Oscar Lambret · NCT05500391Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06065462A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
Phase N/A · 1 location(s) · Tongji Hospital · NCT06279104Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re
Phase 2 · 2 location(s) · Roswell Park Cancer Institute · NCT05231122Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal
Phase 3 · 19 location(s) · M.D. Anderson Cancer Center · NCT04575935INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma
Phase 3 · 1 location(s) · Tongji Hospital · NCT07002346Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
Phase 2 · 4 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07303387APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurr
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT04919629IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05039801A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurr
Phase 2 · 27 location(s) · Yonsei University · NCT06023862Agnostic Therapy in Rare Solid Tumors
Phase 2 · 8 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06638931A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Pliant Therapeutics, Inc. · NCT0627070618F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
NA · 1 location(s) · Peking University First Hospital · NCT07557225A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fa
Phase 2 · 3 location(s) · Mayo Clinic · NCT06639074Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Phase 1 · 3 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT07517198Study of NTB-928 in R/R OC
Phase 1 · 2 location(s) · TeneoSeven, Inc. · NCT07690189A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based
Phase 2 · 50 location(s) · North Eastern German Society of Gynaecological Oncology · NCT05460000Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Phase 2 · 137 location(s) · National Cancer Institute (NCI) · NCT05112601Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Phase 2 · 2 location(s) · Dana-Farber Cancer Institute · NCT06677190Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 1/Phase 2 · 3 location(s) · Mayo Clinic · NCT05920798Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo
Phase 1 · 14 location(s) · National Cancer Institute (NCI) · NCT05950464A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Phase 1/Phase 2 · 81 location(s) · Novartis Pharmaceuticals · NCT04104776
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.